Brief: TG Therapeutics Announces Publication Of Post-HOC Data From The Phase 3 Ultimate I & Ii Trials In Treatment Naive Patients With Relapsing Forms Of MS Published In Frontiers In Immunology
01/06/2026 12:49
BRIEF-TG Therapeutics Announces Publication Of Post-HOC Data From The Phase 3 Ultimate I & Ii Trials In Treatment Naive Patients With Relapsing Forms Of MS Published In Frontiers In Immunology June 1 (Reuters) - TG Therapeutics Inc TGTX.O:
TG THERAPEUTICS ANNOUNCES PUBLICATION OF POST-HOC DATA FROM THE PHASE 3 ULTIMATE I & II TRIALS IN TREATMENT NAIVE PATIENTS WITH RELAPSING FORMS OF MS PUBLISHED IN FRONTIERS IN IMMUNOLOGY
Source text: ID:nGNX4VS1kH
Further company coverage: TGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TG Therapeutics
See all newsBrief: TG Therapeutics Announces Phase 1 Data Evaluating Azer-Cel In Progressive Multiple Sclerosis
TG Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tg Therapeutics Reports Second Quarter 2026 Financial Results And Raises Briumvi® Revenue Guidance
TG Therapeutics Q2 product revenue rises 70% on BRIUMVI sales
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj